<?xml version="1.0" encoding="UTF-8"?>
<p id="Par8">Based on the proven efficacy against SARS-COV, the second-generation protease inhibitor lopinavir, approved for the treatment of HIV in combination with a low dose of ritonavir to increase its plasma half-life, has been used to treat COVID-19 [
 <xref ref-type="bibr" rid="CR10">10</xref>, 
 <xref ref-type="bibr" rid="CR11">11</xref>]. However, despite the use of lopinavir/ritonavir in combination with ribavirin was initially considered a promising therapy for treating COVID-19 infections [
 <xref ref-type="bibr" rid="CR10">10</xref>, 
 <xref ref-type="bibr" rid="CR11">11</xref>], a recent study comparing a group of patients treated with lopinavir/ritonavir and standard treatment (n = 99) versus a second group treated with standard treatment alone (n = 100) [
 <xref ref-type="bibr" rid="CR12">12</xref>] showed that the use of lopinavir–ritonavir association had no benefit compared to standard treatment alone [
 <xref ref-type="bibr" rid="CR12">12</xref>]. The standard treatment was based on the administration of oxygen, invasive and non-invasive ventilation, antibiotics, vasopressor drugs, possible dialysis and extracorporeal oxygenation (ECMO) [
 <xref ref-type="bibr" rid="CR12">12</xref>].
</p>
